ATRIVIEW®, CNS Drug
Neurodegenerative diseases damage neurons, leading to cell death, neuronal network deterioration, and ultimately serious symptoms such as dementia. For instance, amyloid-beta plaque deposits have been known to cause damage to neurons and synapses leading to Alzheimer’s disease. Despite this knowledge, no treatments have been developed to slow or definitively halt damage to neurons or restore brain function.
Genuv takes a new, simple approach: restoring brain functions by inducing the differentiation of neural stem cells in the patient’s brain, thereby generating new nervous tissue. We also restore and maintain the homeostasis of the nervous system. Our lead drug candidate, SNR1611, has been shown to restore CNS functions in preclinical models of amyotrophic lateral sclerosis and Alzheimer’s disease, devastating neurodegenerative diseases. Moreover, this drug candidate is available through simple oral administration.